CELLAVISION AB (publ) - Year-End Bulletin 2007

2008-02-15 - English

January - December
  •    Net sales increased by 36 % to SEK 74.6 million (54.8).
  •    The operating result for the year increased to SEK 3.1 million (-8.6), an improvement of SEK 11.7 million as compared to the previous year. The net result increased to SEK 2.6 million (-8.8).
  •    The net result per share amounted to SEK 0.11 million (-0.37).
  •    Liquid assets amounted to SEK 16.3 million (16.8).
  •    Orders continuously strong on the European market.
  •    New application for body fluids launched in the fall.
  •    An evaluation of a potential future establishment on the Japanese market was initiated.
  •    CellaVision was admitted to trading on First North by the Stockholm Stock Exchange on May 28.
    October - December
  •    Net sales for the fourth quarter increased by 25 % to SEK 19.4 million (15.5).
  •    The operating result amounted to SEK 3.0 million (-1.3) and the net result per share to SEK 0.12 million (-0.05).
  •    The gross profit increased to 73 % (66).
    Important events after the reporting period
  •    As of January 1 the agreement with the distributor Sysmex was altered, allowing CellaVision to sell parallel to Sysmex on the American market.

    CEO's comment
    "It is pleasing to present a positive result for the year and a sales increase of 36 %. A key reason for this is that we further fortified our position on markets where we are already well established, most importantly in Europe. In order to increase the volume of sales in the North American market, in 2008 we will invest in our own organization and sell in parallel to our American distributor. In addition we are evaluating a potential establishment on the Japanese market," says Yvonne Mårtensson, CEO of CellaVision.
    "Another milestone for the company was the initiation of trade at First North, which makes us more visible on the financial market. All of this combined makes me hopeful of CellaVision's development during 2008 and the coming years."
    For more information please contact:
    Yvonne Mårtensson, CEO. Phone: +46 708 33 77 82, e-mail: yvonne.martensson@cellavision.se 
    Johan Wennerholm, CFO. Phone: +46 708 33 81 68, e-mail: johan.wennerholm@cellavision.se

    PDF version: CellaVision AB (publ) - Year-End Bulletin 2007

    Subscribe to updates

    It's possible to subscribe to CellaVision's press releases, financial information by e-mail and SMS.

    Click here to register

    Information request

    Are you looking for some particular information about our company or our business?

    Click here to get in touch


    ABG Sundal Collier AB
    Sten Gustafsson
    +46 8 566 286 93

    Pareto Securities AB
    Christian Lee
    +46 8 402 52 67


    Access our Student Resources

    To access this resource, please provide the following information about yourself.